Annual report pursuant to Section 13 and 15(d)

Acquisition of Pelican Therapeutics - Narrative (Details)

v3.21.1
Acquisition of Pelican Therapeutics - Narrative (Details)
1 Months Ended 3 Months Ended 12 Months Ended
May 31, 2016
USD ($)
Mar. 31, 2018
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Oct. 31, 2018
Sep. 30, 2018
Dec. 31, 2017
director
Acquisition of Pelican Therapeutics              
Discount rate     7.66% 7.83%      
Accrued liabilities     $ 1,614,534 $ 1,676,467      
Other income     $ 255,189 $ (25,557)      
Percentage of non-controlling interest acquired     15.00% 15.00%      
Revenue     $ 2,947,969 $ 3,049,104      
Net loss attributable to Heat Biologics, Inc.     (26,049,737) (20,017,568)      
Net loss     $ 26,381,389 $ 20,384,716      
Pelican Therapeutics, Inc.              
Acquisition of Pelican Therapeutics              
Ownership interest in subsidiary         85.00% 80.00%  
Pelican Therapeutics, Inc.              
Acquisition of Pelican Therapeutics              
Percentage of voting interests acquired in acquisition             80.00%
Other income   $ 200,000          
Percentage of non-controlling interest acquired             20.00%
Amount awarded from CPRIT grant $ 15,200,000            
Pelican Therapeutics, Inc. | Stockholders              
Acquisition of Pelican Therapeutics              
Cash consideration distributed   $ 300,000          
Pelican Therapeutics, Inc. | CEO, Two Directors and Affiliated Companies              
Acquisition of Pelican Therapeutics              
Number of directors | director             2
Percentage of milestone payments that will be paid to related parties             22.70%